Curated News
By: NewsRamp Editorial Staff
December 28, 2024
Investor Alert: Securities Fraud Lawsuit Filed Against Cassava Sciences, Inc.
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- Lead plaintiff deadline is February 10, 2025, giving advantage to act first in securities class action lawsuit against Cassava Sciences, Inc.
- Investors who purchased Cassava securities between Feb 7, 2024, and Nov 24, 2024, can seek lead plaintiff representation by February 10, 2025.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud and corporate misconduct by prosecuting class actions for victims of fraud.
- Defendants allegedly misled investors about the capabilities of Cassava's drug, simufilam, in treating Alzheimer's Disease during the Class Period.
Impact - Why it Matters
This news matters as it highlights alleged misconduct by Cassava Sciences, Inc. and the opportunity for investors to seek legal recourse if they suffered losses. The outcome of this lawsuit could have significant implications for the company and its stakeholders, potentially impacting future investment decisions and the pharmaceutical industry as a whole.
Summary
A securities class action lawsuit has been filed against Cassava Sciences, Inc. by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased Cassava securities during a specific period. The complaint alleges that Cassava's drug, simufilam, was not effective in treating Alzheimer's Disease as claimed by the company. Investors have until February 10, 2025, to participate in the lead plaintiff process.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Investor Alert: Securities Fraud Lawsuit Filed Against Cassava Sciences, Inc.
